RXST Share Price Performance
US$6.26
6.26 (0.00%)
25.7% undervalued intrinsic discount
US$8.43
Fair Value
Price US$6.26
AnalystConsensusTarget US$8.43
AnalystLowTarget US$6.50
AnalystHighTarget US$11.00
Fair ValueUS$8.43
Share Pricen/a
RxSight, Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
RXST Community Narratives
AN
Fair Value
·Fair Value US$8.43 25.7% undervalued intrinsic discount
Entry Into European And Asian Markets Will Unlock New Opportunities
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
Fair Value
·Fair Value US$6.5 3.7% undervalued intrinsic discount
Premium Cataract Focus And Rising Costs Will Limit Long Term Earnings Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$11 43.1% undervalued intrinsic discount
Premium Cataract Adoption And International Expansion Will Drive Strong Long Term Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Is This Lens Maker Mispriced? A Blind Spot in Plain Sight
RxSight (NASDAQ: RXST), maker of the only cataract lens that can be adjusted post-surgery, could be undervalued by an eye-popping margin More than 70% of RxSight Light Adjustable Lens (LAL) patients reported 20/20 or better vision after receiving the lens. Only 36.3% of non-adjustable lens patients reported the same.Read more
HI
US$50
87.5% undervalued intrinsic discount
Fair Value
Profit Margin
30%
Future PE
20x
Price in 2036
US$105.18
Entry Into European And Asian Markets Will Unlock New Opportunities
RxSight bets that expanding beyond the US—especially into Europe and Asia—can bring in new customers for its light-adjustable lens used in cataract surgery. The upside is wider adoption and stronger pricing over time, but the story hinges on one main product while costs rise and regulators could slow overseas growth.Read more
AN
US$8.43
25.7% undervalued intrinsic discount
Fair Value
Profit Margin
11.76%
Future PE
22.78x
Price in 2029
US$10.24
Premium Cataract Focus And Rising Costs Will Limit Long Term Earnings Potential
RxSight bets on patients choosing higher-end cataract options, but that focus could backfire if demand softens or clinics steer people toward cheaper alternatives. Rising costs and a slowdown in expanding its doctor and device network could keep losses lingering longer than many expect.Read more
AN
US$6.5
3.7% undervalued intrinsic discount
Fair Value
Profit Margin
11.77%
Future PE
19.21x
Price in 2029
US$7.91
Premium Cataract Adoption And International Expansion Will Drive Strong Long Term Potential
RxSight sells a cataract lens that can be fine-tuned after surgery, and growing interest from eye doctors could help it win more patients who want premium results. The big question is whether expanding overseas and getting more use from existing clinics can outpace rising costs and new competitors.Read more
AN
US$11
43.1% undervalued intrinsic discount
Fair Value
Profit Margin
11.88%
Future PE
27.87x
Price in 2029
US$13.4
Trending Discussion
No trending discussion available.
Recently Updated Narratives
HI
Is This Lens Maker Mispriced? A Blind Spot in Plain Sight
Fair Value: US$50 87.5% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
RXST: Future Returns Will Rely On Alcon Collaboration Revenue Contribution
Fair Value: US$8.43 25.7% undervalued intrinsic discount
11 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
RXST: Alcon Partnership Will Offset Weaker Utilization And Guidance Cuts
Fair Value: US$6.5 3.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
RxSight, Inc. Key Details
About RXST
- Founded
- 1997
- Employees
- 461
- CEO
- WebsiteView website
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
